Revitalizing therapies in autoimmune diseases: nanoparticles as alternative therapeutic tools

Autoimmune diseases, such as systemic lupus erythematosus (SLE), are complex disorders characterized by an abnormal immune response. In these diseases, the immune system mistakenly identifies different body components as foreign, leading to chronic inflammation and damage to multiple organ and tissue systems. Traditional treatments typically involve immunosuppressive drugs that broadly suppress the immune system. Although these medications can help control symptoms, they also carry significant side effects due to their nonspecific nature. Nanotechnology, through nanomedicine, plays a crucial role in treating diseases, improving drug therapeutic efficacy, and minimizing toxicity. This technology allows for better bioavailability of medications, more precise distribution in the body, and more precise control over drug release. Nanoparticles (NPs) are essential in this process, capable of overcoming biological barriers and directing drugs directly to the affected sites, increasing their effectiveness and reducing side effects. This approach is especially promising in treating autoimmune diseases and cancer. NPs can target specific cells, such as macrophages, monocytes, dendritic cells, and B lymphocytes, to deliver treatments more effectively, with less toxicity and adverse effects. Research in nanotechnology continues to advance, offering hope for more effective and personalized treatments.